en · de · es · fr · pt
cjc-1295-notes.peptides6908.com › Faq › Receptor Action And Pharmacokinetics — Reference Sheet

Receptor Action And Pharmacokinetics — Reference Sheet

By Editorial Desk · published 2026-02-15 · last reviewed 2026-03-17 · Faq

This is a working overview of Drug affinity complex, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.

Receptor Action and Pharmacokinetics

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

CJC-1295 Background and Mechanism

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.

Cjc-1295 at a glance

PropertyValueNotes
Primary targetGHRH receptorG-protein-coupled receptor on pituitary somatotrophs
Half-life, long-acting formSeveral daysExtended by covalent albumin binding
Half-life, short formAbout 30 minutesCleared rapidly by peptidases and kidneys
Route in studiesSubcutaneous injectionUsed in the published human trials
Main measured effectRise in GH and IGF-1Surrogate markers rather than clinical endpoints

Background and Receptor Mechanism

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

Related pages on this site

Analytical Characterization and Storage

Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.

Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.

CJC-1295 Structure And Mechanism

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

Further detail

== Farmed insects not used for protein == Many vegans avoid honey and silk because these require insect farming, even though the insects are not eaten. Silk production involves boiling silk worms alive in their cocoons. The red pigment carmine is produced from powdered bodies of scale insects, so some vegans avoid it. Shellac is produced from a resin secreted by the lac bug on specific trees in Asia. In addition to its use in industry, shellac is incorporated into some fruits, coffee beans, and candies as confectioner's glaze. Some vegans avoid confectioner's glaze because lac bugs may be killed during shellac production. Lac used to produce red dye may be even more injurious to lac bugs because while shellac comes from lac-bug secretions, lac dye's color comes from the insect bodies themselves. Insects are also farmed in large numbers for biological control, where large numbers of parasitic or predatory insects might be reared and then released into the wild to control a pest species. Alternately, in the sterile insect technique, large numbers of sterile male insects may be reared and released in order to reduce wild populations of pest insects or prevent their range expansion, such as with the screwworm. Finally, insects may play an unusual role in specific protein production: fruit flies can be used to generate recombinant proteins which can be used for the production of cell-cultured meat or across many other industries.

Typically, women with GDM exhibit no symptoms (another reason for universal screening), but some women may demonstrate increased thirst, increased urination, fatigue, nausea and vomiting, bladder infection, yeast infections and blurred vision. Pregnant women with these risk factors may need to undergo an early screening in addition to the routine screening.

== The hemocyanin superfamily == The arthropod hemocyanin superfamily is composed of phenoloxidases, hexamerins, pseudohemocyanins or cryptocyanins, and (dipteran) hexamerin receptors. Phenoloxidase are copper-containing tyrosinases. These proteins are involved in the process of sclerotization of arthropod cuticle, in wound healing, and humoral immune defense. Phenoloxidase is synthesized by zymogens and are activated by cleaving an N-terminal peptide. Hexamerins are storage proteins commonly found in insects. These proteins are synthesized by the larval fat body and are associated with molting cycles or nutritional conditions. Pseudohemocyanin and cryptocyanins genetic sequences are closely related to hemocyanins in crustaceans. These proteins have a similar structure and function, but lack the copper binding sites. The evolutionary changes within the phylogeny of the hemocyanin superfamily are closely related to the emergence of these different proteins in various species. The proteins within this superfamily would not be well understood without the extensive studies of hemocyanin in arthropods.

== Selected awards == From 1981 member of the European Molecular Biology Organization (EMBO). From 1982 honorary member of the American Society for Biochemistry and Molecular Biology. Received the Arrhenius Medal in 1983. From 1985 member of the Protein Society, USA. 1985 he was awarded two highly esteemed international scientific prizes given every second year, covering different major areas in biotechnology/biochemistry) as listed below: In Enzyme Engineering by the Engineering Foundation, New York, USA, "in recognition of outstanding contributions to the field of enzyme engineering".(previous winners: Dr. Chibata, subsequent to him Professors Katchalski-Katzir, Fukui, Klibanov, Lilly, Kula/Wandrey (jointly)). For "important contributions in the field of affinity chromatography" by the International Organization on Affinity Chromatography and Biorecognition (first winner K. Mosbach followed by M. Wilchek (1989), C.R. Lowe (1991), I.M. Chaiken (1993), J. Porath (1995), Regnier/Uhlén (1997) (jointly), Kasai (1999) and Vijayalaksmi (2001)... In 1990 he was awarded the gold medal of the Royal Swedish Academy of Engineering Sciences for his contribution to biotechnology, especially on the immobilization of bioactive substances. In 1993 he was awarded the research prize by the Swedish Fund for "Research without Animal Experiments". In April 1999, Biogen Inc., together with its early members including Klaus Mosbach, received the US National Gold Medal of Technology. The recipient of this award was selected by the Department of Commerce and presented by the president William J.

== Biology == The 7kDa proteins are universally found in Sulfolobus, where two copies (Sul7d, Sul7e) are present as separate genes. The proteins are usually named after the species, e.g. Sso7d for the 7d of S. solfataricus and Sac7e for the 7e of S. acidocaldarius. Sul7a and Sul7b are truncated versions of 7d. "Sso7c" does not appear to be a member of this family. S. tokodaii is unusual in that the two copies only differ by one nucleotide and produce the same protein, so its version is simply called Sto7. Across Sulfolobales, Acidianus, Metallosphaera, and "Candidatus Aramenus" also encode a 7kDa DNA-binding protein, named according to the genus name or the species name in an analogous fashion. Each genome may carry anywhere from 1 to 3 versions of the protein.

Sources: en.wikipedia.org

Background from the literature

Gay-Lussac's law A chemical law used for each of the two relationships derived by French chemist Joseph Louis Gay-Lussac and which concern the properties of gases, though the name is more usually applied to his law of combining volumes.

Moreover, a supporting piece of evidence—the result that all proteins contain an integer multiple of 288 amino-acid residues—was likewise shown to be incorrect in 1939. Wrinch replied to the steric-clash, free-energy, chemical and residue-number criticisms of the cyclol model. On steric clashes, she noted that small deformations of the bond angles and bond lengths would allow these steric clashes to be relieved, or at least reduced to a reasonable level. She noted that distances between non-bonded groups within a single molecule can be shorter than expected from their van der Waals radii, e.g., the 2.93 Å distance between methyl groups in hexamethylbenzene. Regarding the free-energy penalty for the cyclol reaction, Wrinch disagreed with Pauling's calculations and stated that too little was known of intramolecular energies to rule out the cyclol model on that basis alone. In reply to the chemical criticisms, Wrinch suggested that the model compounds and simple bimolecular reactions studied need not pertain to the cyclol model, and that steric hindrance may have prevented the surface hydroxyl groups from reacting. On the residue-number criticism, Wrinch extended her model to allow for other numbers of residues. In particular, she produced a "minimal" closed cyclol of only 48 residues, and, on that (incorrect) basis, may have been the first to suggest that the insulin monomer had a molecular weight of roughly 6000 Da.

. In chromatography, the area of a peak is proportional to the number of moles (n) times some constant of proportionality (k), Area = k×n. The number of moles of compound is equal to the concentration (c) times the volume, n = cV. From these equations, the following derivation is made:

=== United States === Emotional mental illnesses is a particular concern in the United States since the U.S. has the highest annual prevalence rates (26 percent) for mental illnesses among a comparison of 14 developing and developed countries. While approximately 80 percent of all people in the United States with a mental disorder eventually receive some form of treatment, on average persons do not access care until nearly a decade following the development of their illness, and less than one-third of people who seek help receive minimally adequate care. The government offers everyone programs and services, but veterans receive the most help, there is certain eligibility criteria that has to be met.

Sources: en.wikipedia.org

Frequently asked questions

How does CJC-1295 raise growth hormone levels?

It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.

Why does the DAC form last longer?

The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.

What remains uncertain about its effects?

Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.

What distinguishes CJC-1295 from natural GHRH?

The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.

Network